Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Mar 13:6:21.
doi: 10.1186/1476-4598-6-21.

Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model

Affiliations

Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model

Susanne Cahill et al. Mol Cancer. .

Abstract

Background: microRNAs (miRNAs) are a group of non-coding single stranded RNAs measuring approximately 22 nucleotides in length that have been found to control cell growth, differentiation and apoptosis. They negatively regulate target genes and have recently been implicated in tumourigenesis. Furthermore, miRNA expression profiling correlates with various cancers, with these genes thought to act as both tumour suppressors and oncogenes. Recently, a point mutation in the BRAF gene leading to a V600E substitution has been identified as the most common genetic change in papillary thyroid carcinoma (PTC) occurring in 29-69% of cases. This mutation leads to aberrant MAPK activation that is implicated in tumourigenesis.

Aim: The aim of this study was to identify the effect that BRAF oncogene has on post-transcriptional regulation in PTC by using microRNA analysis.

Results: A unique miRNA expression signature differentiated between PTC cell lines with BRAF mutations and a normal thyroid cell line. 15 miRNAs were found to be upregulated and 23 miRNAs were downregulated. Several of these up/down regulated miRNAs may be involved in PTC pathogenesis. miRNA profiling will assist in the elucidation of disease pathogenesis and identification biomarkers and targets.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Differentially expressed miRNAs Between BRAF V600E harbouring Cell Lines and Normal Thyroid Cell line. Delta delta CT was performed using Nthy-ori 3-1 as a normal control. The log of the RQ values was used to plot the relative fold change of Nthy-BRAF and KAT10 against Nthy-ori 3-1. miRNAs are on the × axis
Figure 2
Figure 2
Heat map of MiRNA expression. miRNA expression. Each miRNA listed was detected as significantly differentially expressed between BRAF mutated cell lines and N-thy-ori. The delta CT values for each miRNA were used to create the heat map
Figure 3
Figure 3
Hierarchical Clustering of BRAF mutated Cell lines. In (a) The column dendrogram clearly shows cases clustering on the basis of BRAF mutation. To the left are the normal thyroid cell lines with no BRAF mutation and to the right are Nthy-BRAF with V600E mutation. In (b) The denodrogran shows cases again clustering on the basis of BRAF mutation. To the left are the PTCs with BRAF V600E mutation and to the right are the normal thyroid cell lines with no mutation.
Figure 4
Figure 4
Bioanalyser "virtual" gel electrophoresis for N-thy-ori Cell Lines. Lane 1: Nthy-ori rep1; Lane 2:Nthy-ori rep 2; Lane 3: Nthyori rep3

Similar articles

Cited by

References

    1. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6:292–306. doi: 10.1038/nrc1836. - DOI - PubMed
    1. Sheils O. Molecular classification and biomarker discovery in papillary thyroid carcinoma. Expert Rev Mol Diagn. 2005;5:927–946. doi: 10.1586/14737159.5.6.927. - DOI - PubMed
    1. Nikiforova MN, Kimura ET, Gandhi M. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–5404. doi: 10.1210/jc.2003-030838. - DOI - PubMed
    1. Xing M. BRAF mutation in thyroid cancer. Endocrin Rel Cancer. 2005;12:245–262. doi: 10.1677/erc.1.0978. - DOI - PubMed
    1. Finley DJ, Arora N, Zhu B. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab. 2004;89:3214–3223. doi: 10.1210/jc.2003-031811. - DOI - PubMed